** Shares of gene-editing firm Intellia Therapeutics NTLA.O rise 3.4% to $7.54
** NTLA reports Q1 net loss of $1.10 per share, narrower than the net loss of $1.12 a year ago
** Posts Q1 collaboration revenue of $16.63 million, compared with $28.9 million a year ago
** Co says it has cash and cash equivalents of $707.1 million as of March 31, with runway expected into H1 2027
** Including session's moves, stock down 35.4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.